MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
about
Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?A non-coding function of TYRP1 mRNA promotes melanoma growth.DNA damaging agent-based antibody-drug conjugates for cancer therapySustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma
P2860
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
MAPK Pathway Inhibitors Sensit ...... rug Conjugate Targeting GPNMB.
@en
MAPK Pathway Inhibitors Sensit ...... rug Conjugate Targeting GPNMB.
@nl
type
label
MAPK Pathway Inhibitors Sensit ...... rug Conjugate Targeting GPNMB.
@en
MAPK Pathway Inhibitors Sensit ...... rug Conjugate Targeting GPNMB.
@nl
prefLabel
MAPK Pathway Inhibitors Sensit ...... rug Conjugate Targeting GPNMB.
@en
MAPK Pathway Inhibitors Sensit ...... rug Conjugate Targeting GPNMB.
@nl
P2093
P2860
P1476
MAPK Pathway Inhibitors Sensit ...... rug Conjugate Targeting GPNMB.
@en
P2093
April A N Rose
Dennie T Frederick
Ian R Watson
Lawrence Kwong
Marco Biondini
Matthew G Annis
Peter M Siegel
Thomas Hawthorne
Tibor Keler
Zhifeng Dong
P2860
P304
P356
10.1158/1078-0432.CCR-16-1192
P407
P577
2016-08-11T00:00:00Z